ScholarLens Back to search
2014•Primary care diabetesRequires access

Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries

Ugne Sabale, Mattias Ekman, Ola Granström, Klas Bergenheim, Phil C. McEwan

Open publisher page 40 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 40 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Metformin, Dapagliflozin, Sulfonylurea, Medicine, Type 2 diabetes, Diabetes mellitus, Internal medicine, Pharmacology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries — Research Paper | ScholarLens